{"name":"Neuroscience Trials Australia","slug":"neuroscience-trials-australia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNdVVLeDZxUFVPUzRpWk5vZlJjeXFBbjB5ejFIczVpdXZFWGdPU044SHNFTVpmS2xBRVhoRml5aDRSRTlCOEZNVkhHSWlLQVVzeHRWS2hHWTMzck5ucktGQlg1NjJ1bXhsaklDR0dWTGZtY3NoYk13WW9TamQ1X1FXQU5GSlA5eG92NlE?oc=5","date":"2026-02-20","type":"trial","source":"Clinical Trials Arena","summary":"Serina Therapeutics enrols first patient for SER-252 trial - Clinical Trials Arena","headline":"Serina Therapeutics enrols first patient for SER-252 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTFA3czdwNmR5WkQ5cHJ5eFkwNEZWYU5OVnBuVlpEcDdRMVF4bmRLbEJfU0NNTFdhczZVeXkyYmEzaHo4czFSNzFuV0ppZE9FdC1BMXpBb3c0RlB3VXV0YXJUOHhR?oc=5","date":"2026-01-19","type":"pipeline","source":"Labiotech.eu","summary":"10 promising biotechs racing toward a cure for ALS - Labiotech.eu","headline":"10 promising biotechs racing toward a cure for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9QeXh5bTJ5X3FSajd5QmhCNnZtakVOUVdSY1Z2eV9aZUtRMnFKNExidHZqaXM3OW92Rjlac3BLZko1QW1EaHAzSzB1S0MwdlFaVkw3OTd5ZEEtemlqekttbjhqb2RXUFc2QjcxTGVGcUd0cmZadTR5SA?oc=5","date":"2025-11-25","type":"pipeline","source":"Labiotech.eu","summary":"11 neuroscience biotech companies you should know about - Labiotech.eu","headline":"11 neuroscience biotech companies you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPVHZOVnp3bUl1THE5aVdPQmFjU1VzSy1Ub1A1YzBzVVhLdDFtUkNJNXo3RU1Wbm1idkNCQ0FvNXRUWl84dVJ4cnBLOFFmNVM0Q1dza1h6Z2ZDd0IxWmNQMXlQcVctcU54NkNRWGZzOTRNaTUwWTBNUjhVek13Z05PSEd3MWs2MWtMU1R0Y2xRVExRcEFQTWRkZm40al9VdmlBY25FUk5hNldHOWdQcjlsTGozaFZsd1BlWFN1dWxsSy0yY2NxandsUXNsOVlGRlNTYTc5NERkTWxTMlJZcWc5X0FadVl5WW10WVE?oc=5","date":"2025-09-16","type":"trial","source":"BioPharma APAC","summary":"Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer - BioPharma APAC","headline":"Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 into Phase 3 Trial for Advanced Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQR2RVRzRFdXBDc0o3OW9sWERUQ3ZpYW5pUldjdW1vTmRpNjVSRGhsNU1CWjNmRXcxN2Y0TGVZc0g0TGlISE54WGlKRTdEQ0V6RGRHR2FDaFFwUzY0NmpVZnZYNHgyVHV0Ym9RRV94NDlCc0dMalJRZmpkUUxPQUdTbzFld2VqVGZoRVlxczlmc0ZPWVJUVlBMSDZCeklMZzdhUHJpQWNDZ0psZkh2MVNYNFNBLURram00Z29GQ09heldESElLaHprNlQ5ZktLTDFjWWZmYXRlRUk1YWVoVzRYQzl0NWJidVZFVGN3em9Udw?oc=5","date":"2025-03-06","type":"trial","source":"BioPharma APAC","summary":"CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment - BioPharma APAC","headline":"CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxQRkVndWVFUVgzbFhudktOdGF1VER0VVFVTmV6QkJoV0JzMmxWT1NZVDJMd0R4X1ZhTVpvcjFDM3ROQU5LcUNZS05sTWhsNzhQMVpZblhhS1NmSGtxN3ZHMkN5UkI0bDlxVkdzdE5kOFpBMmZnV0U4VFhyYldNUlhJVWZ3MGhHRUVRcGxPSzdrNE8zVmZvM2RWdW1PcnFpSkJBbWh4NzNqWV9ucGdhTXFJU3VxQkF3NkxaY055bHQycXFteFZCOHVpOUVKX2xlbDk0eXNuVHlfZUFRRnRuSU02LUpUaDZ3RDcyUUdKVlZab0hpZDBsRkFDZ0lYejl2YWRhSEE?oc=5","date":"2024-12-23","type":"trial","source":"BioPharma APAC","summary":"CStone Pharmaceuticals Submits Clinical Trial Application in Australia for CS2009, a Tri-Specific Antibody Targeting Solid Tumors - BioPharma APAC","headline":"CStone Pharmaceuticals Submits Clinical Trial Application in Australia for CS2009, a Tri-Specific Antibody Targeting Sol","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNeURla2dpRjNrNmdpVm5FSEc0XzFLcUxILVZmTTVxVEhwQVh6M2FNVDgyNUM5b2tXSmg3Rm9UeGtIT0FZY2wxclFjcVZDR0RtUkx4TGZKMG04MFFTVWJGRURYUEV0aHdVV0RRcUM2cTFUUjdDS1daWWNMTWxkLTU1TWxnaExyVF9URGZtbmdoay1reXdtb3pXV3Atakp6NFVCVnVmbWtmOE9nMUdxN0Z2ZWhjTjc1QQ?oc=5","date":"2024-10-23","type":"trial","source":"Fierce Biotech","summary":"Alto's midphase depression trial falls flat, raising doubts about pitch to disrupt neuropsychiatry R&D - Fierce Biotech","headline":"Alto's midphase depression trial falls flat, raising doubts about pitch to disrupt neuropsychiatry R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOMmVZZ1N5X3RfTktLekgzMk1ORlpVNTBWNjVtam9fS3BkUlc5SWJ3UEhjaDdtZmdtUFRlX3BDYUdYTVp5N0VZeGdSTDJoYV96ci1SYTBnaWlyQ1lnVFB6ekVvaWZkRmZ6MTJILVNsVEZxaHl5ZGJkcXg1aHQybHZOWlJkTGE0aTVjR09PbUUzVkdOS0dyam1TbkxlblJoMzk0bm1aVHlaRXRYUQ?oc=5","date":"2024-10-23","type":"trial","source":"MedCity News","summary":"Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - MedCity News","headline":"Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQQm1vVHZSRkFDZTJQUW1USUt5VU45TG8tX1BZdGxMQ0dDdkkwdThyRzNEQ3VleFNrbGRaUUl2d0JGTFBMX2Q5b1BBUXZTUER0UDJIcTV1ZXVPNEg1RGs3N2NPZDVZREdSSlc0X1hkbVJXQkx5ckVWVG1wT2laNlVUZ1RhWDR3LUVySFlhMnJQTjEwU0JtTlFCUlkwQ2Q4MWxYUHExRQ?oc=5","date":"2021-10-01","type":"trial","source":"The Transmitter","summary":"French pharma firms terminate trials of bumetanide for autism - The Transmitter","headline":"French pharma firms terminate trials of bumetanide for autism","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}